Profiling arbutin as a potent cholinesterase and GSK-3β inhibitor and evaluating its cytotoxicity in SH-SY5Y cells for Alzheimer’s disease therapy
Shirin TARBIAT, Tuğba BAL, Deniz GÜLMEZ · 2026
Read Profiling arbutin as a potent cholinesterase and GSK-3β inhibitor and evaluating its cytotoxicity in SH-SY5Y cells for Alzheimer’s disease therapy by Shirin TARBIAT, Tuğba BAL, Deniz GÜLMEZ (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13528425.txt.
Description
Shirin Tarbiaat and colleagues tested arbutin, a plant compound, as a multi-target candidate against Alzheimer disease. Published in 2026, the lab study measured how beta-arbutin blocks two cholinesterase enzymes that break down acetylcholine, plus GSK-3beta, an enzyme tied to toxic tau tangles. Alzheimer disease brings memory loss with falling acetylcholine and tangled tau protein.
Arbutin blocked all three targets at low micromolar doses, with competitive kinetics against ATP for GSK-3beta and noncompetitive kinetics against its substrate. Applied alone to SH-SY5Y nerve-like cells, it did not harm viability. Docking simulations ranked its binding across the three targets in line with lab results. The authors present arbutin as a natural multi-target lead, still needing animal and human testing.
Catalog record
| CREATOR | Shirin TARBIAT, Tuğba BAL, Deniz GÜLMEZ |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |